Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages
- PMID: 2327400
- DOI: 10.1002/ajh.2830340106
Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages
Abstract
The effect of several iron chelators on iron uptake and release by mouse peritoneal macrophages has been investigated. The 1,2-dimethyl (L1) and 1-ethyl-2-methyl (L1NEt) derivatives of 3-hydroxypyrid-4-one markedly enhanced iron mobilisation from macrophages pulsed with 59Fe-transferrin-antitransferrin immune complexes and were more effective than desferrioxamine, maltol, or mimosine. Release increased with increasing chelator concentration. None of the chelators donated significant amounts of iron to macrophages, and none showed any cytotoxic effect. The synthetic alpha-ketohydroxypyridine chelators may therefore be active in removing iron from the reticuloendothelial system as well as from hepatocytes, and indeed may be superior to desferrioxamine.
Similar articles
-
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.J Clin Pathol. 1987 Apr;40(4):404-8. doi: 10.1136/jcp.40.4.404. J Clin Pathol. 1987. PMID: 3584483 Free PMC article.
-
The effect of synthetic iron chelators on bacterial growth in human serum.FEMS Microbiol Immunol. 1988 Jan;1(1):55-60. doi: 10.1111/j.1574-6968.1988.tb02490.x. FEMS Microbiol Immunol. 1988. PMID: 3272827
-
Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators.FEBS Lett. 1985 Sep 9;189(1):141-4. doi: 10.1016/0014-5793(85)80859-0. FEBS Lett. 1985. PMID: 4029396
-
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.Toxicol Lett. 1995 Oct;80(1-3):1-18. doi: 10.1016/0378-4274(95)03415-h. Toxicol Lett. 1995. PMID: 7482575 Review.
-
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.Hemoglobin. 2006;30(2):183-200. doi: 10.1080/03630260600642450. Hemoglobin. 2006. PMID: 16798643 Review.
Cited by
-
New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.Int J Mol Sci. 2021 May 24;22(11):5546. doi: 10.3390/ijms22115546. Int J Mol Sci. 2021. PMID: 34074010 Free PMC article. Review.
-
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.Cells. 2020 Jun 12;9(6):1456. doi: 10.3390/cells9061456. Cells. 2020. PMID: 32545424 Free PMC article. Review.
-
Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.Molecules. 2015 Nov 23;20(11):20841-72. doi: 10.3390/molecules201119725. Molecules. 2015. PMID: 26610453 Free PMC article. Review.
-
Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients.Int J Mol Sci. 2022 Jan 25;23(3):1364. doi: 10.3390/ijms23031364. Int J Mol Sci. 2022. PMID: 35163288 Free PMC article.
-
Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone.PLoS Negl Trop Dis. 2023 Aug 31;17(8):e0011607. doi: 10.1371/journal.pntd.0011607. eCollection 2023 Aug. PLoS Negl Trop Dis. 2023. PMID: 37651502 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical